ImmunoGen Inc. and its directors allegedly left several key details out of a proxy statement for the company’s proposed acquisition by AbbVie Inc., according to a shareholder lawsuit.
The biotechnology company presented the $10.1 billion buyout agreement to investors without the necessary financial metrics for them to cast informed votes, according to the suit filed Thursday in US District Court for the Southern District of New York.
AbbVie’s proposed deal, if approved, would pay out $31.26 per share to bring the drugmaker’s capabilities and Elahere cancer treatment under its control.
Shareholders haven’t seen sufficient financial forecasts for ImmunoGen, analyses ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.